Newsroom

ORPHELIA Pharma raises 4 m€ to fund its commercial operations and clinical developments

Gilles Alberici, CEO and Jeremy Bastid, COO, will participate to the J.P. Morgan 38th Annual Healthcare Conference to be held 13-16 January 2020 in San Francisco, California, USA

initiative Octalfa wishes you a happy new year 2020

It has been a busy year for our Endowment Fund and Corporate Foundation!

The 22th of november 2019, the board of directors of the Foundation Dominique & Tom Alberici decided to support “APPEL” and “le Gai-Rire”,

Ivozall® is an essential medicine intended for the treatment of relapsed or refractory Acute Lymphoblastic Leukaemia in children

The 18th of september 2019, the board of directors of our Endowment Fund Dominique & Tom Alberici decided to support “Douleurs sans Frontières” and “Anyma”, two projects in Madagascar.

The 18th of september 2019, the board of directors of the Foundation Dominique & Tom Alberici decided to support “Odynéo” and “Léthé Musicale”,

Baikowski® has signed a memorandum of understanding for the acquisition, subject to the satisfaction of conditions precedent, of Mathym SAS, a company located at Champagne-au-Montd’Or in France.

Alizé Pharma 3 raises €67 million ($75 million) in Series A from a strong international syndicate

ORPHELIA Pharma announces today that it has entered into a collaboration agreement with the epilepsy specialist Desitin GmbH to distribute Kigabeq® in Germany.

ORPHELIA Pharma executes a collaboration and license agreement with Gustave Roussy cancer centre for the development of the first pediatric formulation of temozolomide

This sixth newsletter is packed full of information seeing as the semester has been extremely busy for both the Dominique & Tom Alberici Foundation and our Endowment Fund.

The 17th of may 2019, the board of directors of the Foundation Dominique & Tom Alberici decided to support “le Sourire d’Onja”, “Sauvegarde 69”, and “Au-delà de nos Handicaps”,

We organised the Alberici Foundation Meetings on the 17th and 18th April to celebrate the 10th anniversary of the Alberici Foundation and our 100th project. Thank you to those who joined us on Wednesday evening. Some 280 of us attended the philanthropic evening of music and festivities, and it was great fun. Thanks also to those who support us but were unable to attend!

Alizé Pharma 3 to present data from its AZP-3404 program in syndromes of severe insulin resistance at ENDO 2019

Millendo Therapeutics Initiates Pivotal Phase 2b/3 Clinical Study of Livoletide for the Treatment of Prader-Willi Syndrome.

The 3rd phase, JHAM3, launched in 2018 with a collection of items such as adaptive equipment, games, educational toys and books, stationery, school supplies, clothing and household linen.
The 33 m3 container left France on the 28th December en route for Toamasina in Madagascar, and we distributed the equipment to ten Malagasy organisations during our mission between the 3rd and 17th March.

Millendo Therapeutics Announces ENDO 2019 Presentations on Livoletide for Prader-Willi Syndrome and Nevanimibe for Classic Congenital Adrenal Hyperplasia.

The 8th of february 2019, the board of directors of the Fondation Dominique & Tom Alberici decided to support the MIETE by helping to organise its Fest’Dif festival in Villeurbanne (Rhône) on the 5th and 6th July 2019, which aims to promote difference and diversity.

Our Corporate Foundation and Endowment Fund are as busy as ever, with 4 projects supported this half-year and the effective implementation of the 3rd phase of the JHAM project (Jumelage Handicap Aide Madagascar – Madagascar Disability Support Twinning)…

The 19th of october 2018, the board of directors of the Fondation Dominique & Tom Alberici decided to support Magie à l’hôpital for acquisition of digital and tactile adapted tablets for the hospitalized children at Necker Hospital, and Les Chiens du Silence (Dogs of Silence), which educates and provides earphone dogs to deaf or hard of hearing people.

Alizé Pharma 3 moves forward with building a transatlantic biopharmaceutical company focused on rare endocrine and metabolic diseases

The JHAM 2 project aims to implement a collective educational programme in 2017 following an observation phase.
A container has been sent in june 2017